Evidence map›Paper›PMID 24753353›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2014

Gut feelings about smoking and coffee in Parkinson's disease.

Pascal Derkinderen, Kathleen M Shannon, Patrik Brundin

Open access · greenAbstract read
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 113 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. The Gut-Brain Axis: Two Ways Signaling in Parkinson's Disease.Cellular and molecular neurobiology · 2022
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Pascal DerkinderenCHU Nantes, Department of Neurology, F-44093, France; Inserm, U913, Nantes, F-44093, France.
Kathleen M Shannon
Patrik Brundin
Centre Hospitalier Universitaire de Nantes · FRRush University Medical Center · USVan Andel Institute · US

Funding

Parkinson's Disease Research Trial: Clinical CenterU10NS044475 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI SHANNON, KATHLEEN M · 2002 to 2014
$882k
NINDS NIH HHS U10 NS044475
6 · The paper itself

Abstract

Strong epidemiologic evidence suggests that smokers and coffee drinkers have a lower risk of Parkinson's disease (PD). The explanation for this finding is still unknown, and the discussion has focused on two main hypotheses. The first suggests that PD patients have premorbid personality traits associated with dislike for coffee-drinking and smoking. The second posits that caffeine and nicotine are neuroprotective. We propose an alternative third hypothesis, in which both cigarette and coffee consumption change the composition of the microbiota in the gut in a way that mitigates intestinal inflammation. This, in turn, would lead to less misfolding of the protein alpha-synuclein in enteric nerves, reducing the risk of PD by minimizing propagation of the protein aggregates to the central nervous system, where they otherwise can induce neurodegeneration.

Indexed as

MicrobiotaSmokingCoffeeGastrointestinal TractHumansParkinson DiseaseRisk FactorsCoffeeenteric nervous systemnicrobiotaParkinson's disease

Identifiers

PMID24753353
PMCPMC4107006
OpenAlexW1897759802

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.